The associations between hypertension and the risks of long-term liver-related and other adverse clinical outcomes in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) were recently explored in the observational study by Zhou and coworkers1. However, a number of important unmeasured or insufficiently captured confounders that may substantially affect both the exposure of interest (ie, hypertension) and the outcomes were not accounted for in their observational study1.
Journal of Hepatology published a clinical update in Research Highlights on 09 Jan 2026.
The item focuses on Hypertension and Long-Term Adverse Clinical Outcomes in MASLD: Sensitivity Analyses for Unmeasured or Uncontrolled Confounding.
Review the original article for the full source wording and details.